NeoGraph Analytics
Medical DevicesGlobal2026 – 2032

Insulin Delivery Devices Market Size, Share & Forecast 2026-2032

Insulin delivery devices at $21.90B in 2026, reaching $34.56B by 2032 at 7.9% — and why disclosed pump revenue fills 93% of the published pump segment.

Revenue, 2026

$21.9B

Forecast, 2032

$34.6B

CAGR, 2026-2032

7.9%

Report Coverage

Global

Code: insulin-delivery-devices-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

Insulin delivery is the best-instrumented market in this batch, because three companies publish patient counts alongside revenue, and that turns an unauditable dollar figure into checkable arithmetic. Published 2024 estimates span $10.11 billion to about $35.6 billion — a 3.52x spread — with stated CAGRs running 5.17% to 15.3% inversely to the bases, which is what reverse-engineered rates look like. We publish Global Market Insights' October 2026 series, the only one whose 2025 product and regional tables both sum exactly to its own total: $21.90 billion in 2026 to $34.56 billion by 2032 at 7.9%. Then the denominators do their work. Insulet's $2.7 billion of Omnipod revenue is essentially all disposable pods — a consumable — against a global pump-consumables segment of $900 million, a factor of three; reclassify pods as tubeless pumps and one company becomes 90% of a $3.00 billion segment. Take the whole pump side, $7.40 billion, and three pure-plays disclose 52% of it while none of them is the installed-base leader; add Medtronic Diabetes and Ypsomed's former unit and five disclosures consume 93.3%, leaving about $495 million for Roche, Sequel, Medtrum, Equil, SOOIL and every Chinese and Indian vendor. The per-patient figures are the useful output: $4,500 a year per Omnipod user, $2,865 per Beta Bionics user, about $3,383 per Tandem supply-ordering customer. Inverting the published total gives 1.6 to 2.6 million pump users worldwide — 0.27% to 0.44% of the 589 million adults the IDF counts with diabetes, 252 million of whom are undiagnosed. And the 7.9% headline averages a 2%-growth needles-and-strips business with an 11-to-54%-growth pump business. Worse, revenue is about to stop tracking adoption: Tandem's 2026 guidance carries $85-95 million of headwind purely from pharmacy-channel pricing while shipments rise 10-11%.

02

Key Highlights

1

Headline

$21.90 billion in 2026 to $34.56 billion in 2032 at 7.9%, from Global Market Insights' own published 2026 base and stated rate (implied 7.90%)

2

Published 2024 estimates span 3.52x ($10.11B-$35.6B), with CAGRs of 5.17% to 15.3% running inversely to the bases

3

Insulet's $2.7 billion of disposable pod revenue is 3.0x the entire $900 million global pump-consumables segment one publisher sizes

4

Five disclosures consume 93.3% of the $7.40 billion published pump side; three pure-plays alone are 52%, and none of them is the installed-base leader

5

Revenue per patient is directly checkable: $4,500 a year per Omnipod user (600,000+ users), $2,865 per Beta Bionics user (35,011 users), about $3,383 per Tandem supply customer

6

Inverting the published pump total gives 1.6-2.6 million pump users worldwide — 0.27% to 0.44% of the 589 million adults with diabetes the IDF counts, 252 million of them undiagnosed

7

The 7.9% blended rate averages a 2%-growth commodity business (needles, syringes, strips, about $5.00 billion) with companies that grew 10.7% to 54% in FY2025

8

Tandem's 2026 guidance includes $85-95 million of headwind from pay-as-you-go pharmacy pricing while it guides pump shipments up 10-11% — revenue and patients diverging

03

Market Overview

Market Context

Insulin delivery is two markets filed under one heading, and the filing error is what produces a 3.5x spread. One of them is a commodity: pen needles, insulin syringes and test strips, about $5.00 billion a year on one publisher's figures, compounding at 2% to 4.5%, sold through pharmacy and retail at low unit prices into every country that has insulin at all. The other is automated insulin delivery: pumps, patch pods, infusion sets and the algorithms that run them, about $7.40 billion, whose vendors grew between 10.7% and 54% in FY2025 and whose patient population is on our arithmetic between 1.6 and 2.6 million people. The first market is defined by insulin access; the second by reimbursement, diagnosis and clinical inertia. They share a word and nothing else. The scale of the gap between them is best seen through the population: the IDF counts 589 million adults living with diabetes, 252 million of whom do not know it, which puts total device spend at about $34 per person with diabetes per year and pump penetration at under half of one percent. Everything that gets written about this market — the algorithms, the interoperability filings, the patch-pump launches, the type 2 expansion — concerns that fraction of a percent. And the supplier structure makes the larger half unauditable: Novo Nordisk and Eli Lilly supply most of the world's pens with the hardware cost embedded in the insulin price, so the biggest single segment of the published market, roughly 38% of it, has no disclosed revenue line anywhere on earth.

Published insulin delivery device estimates for 2024 run from $10.11 billion to about $35.6 billion — a 3.52x spread — and the stated CAGRs run from 5.17% to 15.3% in the wrong direction, with the lowest base claiming the highest growth. We publish Global Market Insights' October 2026 series, the only one in the set whose own segment and regional tables sum exactly to its own total: $21.90 billion in 2026 rising to $34.56 billion by 2032 at 7.9%. This market has unusually good denominators, and they expose two things. First, a taxonomy failure: Insulet's $2.7 billion of Omnipod revenue is almost entirely disposable pods, a consumable, against a global pump-consumables segment of $900 million — a factor of three. Second, and more useful than any dollar figure: Insulet, Tandem and Beta Bionics publish patient counts alongside revenue, so revenue per patient is directly checkable at $4,500, roughly $3,383 and $2,865 a year. Inverting the published pump-side total of $7.40 billion gives a global pump population of 1.6 to 2.6 million people — under half of one percent of the 589 million adults the IDF counts as living with diabetes, 252 million of whom do not know it.

Market Stage

Growth

Adoption Level

Pens and syringes near-universal where insulin is available; pumps under 0.5% of people with diabetes

Key Trends

Patch pumps are taking the category: Insulet grew Omnipod revenue 31.6% to $2.7 billion in FY2025 and passed 600,000 estimated active users globally, ranking first in new customer starts in both the United States and EuropeType 2 diabetes, not type 1, is where the pump growth now comes from, which is what turns a 1.6-to-2.6-million-patient market into a plausible multi-million one — and it is the explicit driver Insulet cites for its FY2025 outperformanceThe pharmacy channel is replacing durable medical equipment: Beta Bionics' pharmacy sales rose 295% in the fourth quarter of 2025 and the pharmacy share of its new patient starts went from a high single-digit percentage to the high twenties in one yearThat channel shift breaks the revenue series. Tandem's 2026 guidance of $1.065-1.085 billion includes $85-95 million of headwind purely from moving United States customers to pay-as-you-go pricing with no upfront pump reimbursement, while it guides pump shipments up 10-11%Automated insulin delivery is now the product, not the pump: Medtronic's fiscal 2025 Diabetes growth of 10.7% is attributed to MiniMed 780G installed base and CGM attachment rates, and it has filed 510(k)s for an interoperable pump and algorithm to pair with an Abbott-based sensorStructural separation is under way at the largest incumbent: Medtronic announced its intent to separate the Diabetes business into a standalone public company within 18 months, which will for the first time put a pump-and-CGM pure play of that scale on public record
04

Market Forecast & Data

Market Growth Forecast
2026-2032 · CAGR 7.9%

Base Year (2026)

$21.9B

Forecast (2032)

$34.6B

CAGR (2026-2032)

7.9%

Market size by year, 2026-2032, in USD Billion.
YearMarket size ($ Billion)
2026Base year$21.90B
2027$23.63B
2028$25.50B
2029$27.51B
2030$29.68B
2031$32.03B
2032$34.56B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. Modelled at Global Market Insights' stated 7.9% CAGR from its own published 2026 base. How these figures are produced.
Forecast Analysis

Our 7.9% is Global Market Insights' own rate on its own base, and the series reproduces its stated rate exactly. The problem is not the arithmetic, it is that the rate is a weighted average of two businesses that no operator experiences together. The pump side compounds at the rate its vendors actually posted in FY2025 — Beta Bionics 54%, Insulet 31.6%, Tandem 12%, Medtronic Diabetes 10.7% — and the commodity side at 2% to 4.5% on the same publisher's own segment figures. A reader forecasting pumps at 7.9% will understate by half; a reader forecasting pen needles at 7.9% will overstate by double. The structural question that determines which way the blend drifts is type 2 adoption, which Insulet names as the main driver of its outperformance. Moving pump penetration from 0.3-0.4% of the diabetic population to 1% would roughly triple the pump side and would shift the blended rate upward by several points on its own. Against that, two forces suppress the measured series. The first is the pharmacy channel: pumps paid as a recurring supply rather than reimbursed upfront generate less revenue per new patient in year one, and Tandem has quantified that at $85-95 million of 2026 headwind against 10-11% shipment growth. The second is simply the commodity base, which is large, inelastic and tracks insulin volumes rather than technology. Readers should forecast the two halves separately, and should prefer patients, pumps shipped and installed base — all of which Insulet, Tandem and Beta Bionics publish — over revenue, which is about to become a worse proxy for adoption than it already is.

05

Market Dynamics

  • Type 2 diabetes adoption of pump therapy, which Insulet names as the main driver of its 31.6% FY2025 Omnipod growth and which is the only mechanism that can move pump penetration above the current 0.3-0.4% of people with diabetes
  • Automated insulin delivery algorithms paired with continuous glucose monitoring, now the actual product being bought: Medtronic cites MiniMed 780G installed base and CGM attachment rates as its fiscal 2025 growth drivers
  • Pharmacy-channel distribution, which removes the durable medical equipment paperwork barrier — Beta Bionics' pharmacy sales grew 295% in Q4 2025 and Tandem is migrating its whole United States base
  • A very large and still-growing population: the IDF Diabetes Atlas 11th edition counts 589 million adults aged 20-79 with diabetes in 2025, projected to reach 853 million by 2050
  • Geographic expansion of patch pumps into markets with no prior pump infrastructure: Insulet launched Omnipod 5 in nine new markets during 2025 and grew international revenue 44.1%
  • Interoperability mandates and filings that unbundle the pump from the sensor, including Medtronic's 510(k) submissions for an interoperable pump and algorithm, which widens the addressable base for every algorithm vendor
06

Market Segmentation

By Type

  • Tubeless patch pumps
  • Tubed insulin pumps
  • Pump consumables and infusion sets
  • Disposable insulin pens
  • Reusable insulin pens
  • Pen needles
  • Insulin syringes
  • Jet injectors

By End User

  • Home care and self-administration
  • Retail and pharmacy channel
  • Durable medical equipment distributors
  • Hospitals and clinics
  • Ambulatory surgical centres

By Application

  • Type 1 diabetes
  • Type 2 diabetes on insulin
  • Gestational diabetes
  • Automated insulin delivery with continuous glucose monitoring
  • Multiple daily injection therapy
07

Competitive Landscape

I

Insulet Corporation

Acton, Massachusetts, United States

The company the published taxonomy cannot place. Its $2.7 billion of Omnipod revenue is almost entirely disposable pods — a consumable — against a global pump-consumables segment one publisher sizes at $900 million, a factor of three; classified instead as a tubeless pump it would be 90% of that segment. It also publishes a patient count, which makes it the anchor for every per-user calculation in this report. Share is not disclosed and we assign none.

FY2025 total revenue approximately $2.73 billion, up 31%, of which Omnipod was $2.7 billion (up 31.6% reported, 30.3% constant currency) and Drug Delivery $34.1 million. International revenue $754.3 million, up 44.1%. Operating income $473.8 million, or 17.5% of revenue. More than 600,000 estimated active Omnipod users globally at 31 December 2025, which at $2.7 billion is $4,500 per user per year. Ranked first in new customer starts in both the United States and Europe in 2025, with Omnipod 5 launched in nine new markets. Growth attributed mainly to type 2 diabetes adoption.

M

Medtronic plc, Diabetes

Galway, Ireland (Diabetes operational base: Northridge, California, United States)

Holds the largest installed pump base globally and is the reason the published pump segment runs out of room: adding any plausible pump-only figure for Medtronic to the three pure-plays fills the segment. Its $2.755 billion includes continuous glucose monitoring, which the published market does not count at all, so it cannot be compared directly. No pump count and no share are disclosed.

Fiscal 2025 Diabetes revenue $2.755 billion, up 10.7% reported and 11.5% organic; fourth-quarter revenue $728 million, up 10.4% reported and 12.0% organic, a sixth consecutive quarter of double-digit organic growth. Growth attributed to adoption of the MiniMed 780G automated insulin delivery system, a growing installed base and strong CGM attachment rates, with international pumps up low twenties. Secured FDA approval for the Simplera Sync CGM with MiniMed 780G and submitted 510(k) applications for an interoperable pump and algorithm to pair with an Abbott-based sensor. Medtronic announced its intent to separate Diabetes into a standalone public company within 18 months.

T

Tandem Diabetes Care, Inc.

San Diego, California, United States

The clearest illustration of why this market is about to be mismeasured. Tandem is migrating United States customers to pay-as-you-go pharmacy pricing with no upfront pump reimbursement, and its own 2026 guidance carries $85-95 million of headwind from the change while it guides pump shipments up 10-11%. Reported revenue and patients served are moving in opposite directions. No share is disclosed.

FY2025 worldwide sales approximately $1.015 billion, up 12%, with fourth-quarter sales of $290.4 million. More than 126,000 pumps shipped worldwide during 2025 — more than 86,000 in the United States and more than 40,000 internationally — with 38,000 shipped in the fourth quarter. More than 300,000 United States customers regularly order supplies, which at $1.015 billion is roughly $3,383 per customer per year before counting international customers. 2026 guidance $1.065-1.085 billion including the business-model headwind.

B

Beta Bionics, Inc.

Irvine, California, United States

The smallest disclosed participant and the most precisely measurable: $100.3 million of FY2025 revenue across an installed base of exactly 35,011 users, or $2,865 per user per year. Its channel mix is the leading indicator for the whole market — pharmacy sales grew 295% in the fourth quarter. Share is not disclosed and we assign none.

FY2025 net sales $100.3 million, up 54% from $65.1 million, at a 55.4% gross margin, split $75.8 million durable medical equipment and $24.4 million pharmacy. Fourth-quarter net sales $32.1 million, up 57%, with DME up 24% to $22.3 million and pharmacy up 295% to $9.8 million. Close to 20,000 new users adopted the iLet bionic pancreas in 2025, taking the installed base to 35,011; fourth-quarter new patient starts 5,592, up 37%. Pharmacy share of new patient starts rose from a high single-digit percentage to the high twenties in one year. Management addressed an FDA warning letter tied to quality-system observations on the fourth-quarter call.

Y

Ypsomed Holding AG

Burgdorf, Switzerland

Has left the market during the period under review. Its Diabetes Care business — the mylife pump and pen portfolio — recorded CHF 236.9 million in FY2024/25, the last year it was a reported segment, and was sold during FY2025/26. Ypsomed now reports as a drug-delivery contract manufacturer. Named and dated, not sized forward.

FY2025/26 consolidated revenue CHF 731.0 million against CHF 748.9 million the prior year, with Delivery Systems — the core contract drug-delivery business — at CHF 601.5 million, up about 20% from CHF 502.3 million. Diabetes Care recorded CHF 236.9 million in FY2024/25. EBIT more than doubled to CHF 246.1 million, partly on the book gain from completing the sale of mylife Diabetes Care AG and Ypsotec AG. Dividend proposed to double to CHF 4.40 per share.

R

Roche Diabetes Care (F. Hoffmann-La Roche AG)

Basel, Switzerland

Holds the Accu-Chek pen, pump and infusion-set portfolio with a long-established European and emerging-market base, reported inside Roche Diagnostics with no insulin-delivery split. One of the vendors that must fit, with Sequel, Medtrum, Equil, SOOIL and every Chinese and Indian manufacturer, into the roughly $495 million the published pump segment has left after five disclosures. Named, not sized.

Accu-Chek insulin pumps, infusion sets and pen systems, distributed principally through pharmacy and retail channels in Europe, Latin America and Asia. No insulin-delivery device revenue is separately disclosed in Roche's segment reporting.

N

Novo Nordisk A/S and Eli Lilly and Company

Bagsvaerd, Denmark and Indianapolis, Indiana, United States

Between them supply most of the world's insulin pens, which is the largest single segment of this market at about 38% of one publisher's 2025 total. Neither reports pen hardware separately from the insulin inside it, so the pen segment — the biggest part of the published market — has no disclosed revenue line anywhere. Named, not sized.

Disposable and reusable insulin pen systems supplied as part of insulin franchises, with the device cost embedded in the drug price and not separately reported. Their absence from any device revenue disclosure is why the pen segment of the published market cannot be independently checked at all.

08

Recent Developments

26
2026Insulet Corporation

Reported FY2025 results on 18 February 2026: Omnipod revenue of $2.7 billion, up 31.6%, with international revenue up 44.1% to $754.3 million, and disclosed more than 600,000 estimated active Omnipod users globally as of 31 December 2025 — a tenth consecutive year of 20%-plus constant-currency growth, driven mainly by type 2 diabetes adoption.

26
2026Tandem Diabetes Care, Inc.

Reported FY2025 results on 19 February 2026 with worldwide sales of about $1.015 billion and more than 126,000 pumps shipped, and guided 2026 to $1.065-1.085 billion including $85-95 million of headwind from migrating United States customers to a pay-as-you-go pharmacy model with no upfront pump reimbursement, while guiding United States pump shipments up 10-11%.

26
2026Beta Bionics, Inc.

Reported FY2025 net sales of $100.3 million on 17 February 2026, up 54%, with an installed base of 35,011 iLet users after close to 20,000 new adoptions during the year, and fourth-quarter pharmacy-channel sales up 295% to $9.8 million as the pharmacy share of new patient starts rose from a high single-digit percentage to the high twenties.

26
2026Ypsomed Holding AG

Completed the sale of mylife Diabetes Care AG, formerly Ypsomed Diabetes Care AG, during FY2025/26, removing from the market a business that had recorded CHF 236.9 million of revenue in FY2024/25, and reported group EBIT more than doubling to CHF 246.1 million partly on the resulting book gain.

25
2025Medtronic plc

Announced on 21 May 2025 its intent to separate the Diabetes business into a standalone public company within 18 months, preferring an initial public offering followed by a split-off, alongside fiscal 2025 Diabetes revenue of $2.755 billion, up 10.7% reported and 11.5% organic.

25
2025International Diabetes Federation

Published the IDF Diabetes Atlas 11th edition on 7 April 2025 at the World Diabetes Congress in Bangkok, counting 589 million adults aged 20-79 living with diabetes, of whom 252 million are unaware of their condition, and projecting 853 million adults by 2050.

09

Regulatory Landscape

Insulin pumps are Class II devices in the United States and have historically cleared through the FDA 510(k) pathway. Since 2019 FDA has recognised an Alternate Controller Enabled infusion pump pathway — the interoperable pump, or ACE pump — which permits a pump to be cleared for use with a compatible controller and algorithm from a different manufacturer. Medtronic submitted 510(k) applications under that framework for an interoperable pump and algorithm during fiscal 2025.Automated insulin delivery requires three separate authorisations that must then be shown to work together: the pump as an ACE pump, the sensor as an integrated continuous glucose monitor (iCGM), and the dosing algorithm as interoperable automated glycaemic controller software. A system is only marketable when all three clearances exist and compatibility is demonstrated, which is why Medtronic's Simplera Sync approval for use with MiniMed 780G was reported as a discrete regulatory event.Channel classification determines reimbursement. Pumps supplied as durable medical equipment are paid under Medicare Part B with upfront reimbursement for the device; pumps supplied through the pharmacy channel are paid under Part D or commercial pharmacy benefit as a recurring supply, with no upfront payment. That distinction, not any clinical change, is what produces the $85-95 million revenue headwind in Tandem's 2026 guidance.FDA quality system regulation at 21 CFR part 820 — now converging on ISO 13485 under the Quality Management System Regulation — is the enforcement surface for this category, and warning letters are a live risk for single-product companies: Beta Bionics addressed one tied to quality-system observations on its fourth-quarter 2025 earnings call.EU Medical Device Regulation 2017/745 governs pumps, pens and infusion sets placed on the EU market, with notified-body conformity assessment and post-market clinical follow-up; insulin pens supplied as part of a drug-device combination are additionally assessed under the medicinal product framework, which is one reason pen hardware revenue is never reported separately.Pen needles, insulin syringes and infusion sets are regulated as Class II sharps with 510(k) obligations and, in the United States, are additionally subject to the Needlestick Safety and Prevention Act's requirements on sharps injury protection — a commodity regulatory regime quite unlike the pump pathway, which is part of why a single market definition spanning both is unstable.
10

Research Methodology

Secondary research

  • Global Market Insights, Insulin Delivery Devices Market, report GMI1649, published October 2026 — $18.50B (2024), $20.00B (2025), $21.90B (2026), $42.96B (2035), 7.9% (2026-2035), with pumps $6.50B, pens 38%, pen needles $3.00B, syringes 8%, pump consumables $900M and strips 2% for 2025
  • Insulet Corporation, Reports Fourth Quarter and Full Year 2025 Results, 18 February 2026 — Omnipod revenue $2.7B (+31.6%), Drug Delivery $34.1M, international $754.3M (+44.1%), more than 600,000 estimated active Omnipod users globally at 31 December 2025
  • Tandem Diabetes Care, Inc., Announces Fourth Quarter and Full Year 2025 Financial Results and 2026 Financial Guidance, 19 February 2026 — worldwide sales about $1.015B (+12%), more than 126,000 pumps shipped, more than 300,000 United States supply-ordering customers, 2026 guidance including $85-95M of pay-as-you-go headwind
  • Medtronic plc, fourth quarter and fiscal year 2025 results, 21 May 2025, and Form 10-K for fiscal 2025 (SEC EDGAR, CIK 1613103) — Diabetes revenue $2.755B (+10.7% reported, +11.5% organic), including CGM; intent to separate Diabetes announced
  • Beta Bionics, Inc., Announces Fourth Quarter and Full Year 2025 Financial Results, 17 February 2026 — net sales $100.3M (+54%), DME $75.8M, pharmacy $24.4M, installed base 35,011 users
  • Ypsomed Holding AG, FY2025/26 annual results — group revenue CHF 731.0M, Delivery Systems CHF 601.5M, Diabetes Care CHF 236.9M in FY2024/25, completion of the mylife Diabetes Care AG disposal
  • International Diabetes Federation, IDF Diabetes Atlas 11th edition, published 7 April 2025 — 589 million adults aged 20-79 with diabetes, 252 million undiagnosed, 853 million projected by 2050
  • DelveInsight, insulin delivery devices market (2025 report) — approximately $35.6B (2024) to $53.0B (2032) at 5.17%
  • Credence Research, insulin delivery devices market — $10.11B (2024) to $31.57B (2032) at 15.3%; page carries content about asthma, COPD and cystic fibrosis inside an insulin report
  • SkyQuest Technology, insulin delivery devices market — $18.02B (2024) to $33.11B (2032) at 7.9%; and MarketsandMarkets, insulin delivery device market — $30.8B (2023) to $46.2B (2028) at 8.5%

Validation: The 2026 base is Global Market Insights' own published 2026 figure of $21.90 billion, unaltered; the 2032 endpoint is derived by compounding it at GMI's own stated 7.9% rate and is labelled as interpolation. The internal check is that the implied rate between our endpoints is 7.90%, identical to the stated rate. GMI was chosen because it is the only source in the set that is internally consistent — its 2025 product segments sum exactly to its $20.00 billion total, and so does its 2025 regional table, which no other source here can demonstrate — because it is the most recently published with a dated base year, and because its explicit taxonomy is what made the checks below possible at all. Five grounding tests were run against FY2025 reported revenue and the patient counts companies publish alongside it. First, a taxonomy test: Insulet's $2.7 billion of Omnipod revenue is almost entirely disposable pods, which is a consumable, and that is 3.0 times GMI's entire global pump-consumables segment of $900 million; reclassifying pods as tubeless pumps instead makes Insulet 90% of that $3.00 billion segment, leaving $300 million for Ypsomed, Medtrum, Equil, Sequel and every other patch-pump vendor. Second, a containment test: GMI's pump-attributable total for 2025 is $6.50 billion of pumps plus $0.90 billion of pump consumables, or $7.40 billion. Insulet, Tandem and Beta Bionics together disclose $3,849 million, which is 52.0% of it, and none of the three is the global installed-base leader. Adding Medtronic Diabetes at $2,755 million and Ypsomed's former Diabetes Care segment at about $301 million takes five disclosures to $6,905 million, or 93.3%, leaving about $495 million for Roche, Sequel, Medtrum, Equil, SOOIL, every third-party infusion set and every Chinese and Indian vendor. The Medtronic figure includes continuous glucose monitoring revenue that GMI does not count in this market, so it is an upper bound rather than a pump figure, and the pure-play subtotal carries the finding on its own. Third, a revenue-per-patient test, possible because three companies publish both numbers: Insulet $2,700 million over more than 600,000 active users is $4,500 per user per year; Beta Bionics $100.3 million over exactly 35,011 users is $2,865; Tandem $1,015 million over more than 300,000 United States supply-ordering customers is about $3,383 before counting international customers. Because the user counts are floors, these are upper bounds. Fourth, inverting the published total: $7.40 billion divided by $4,500 gives 1.64 million pump users worldwide and divided by $2,865 gives 2.58 million, so GMI's pump side implies a global pump population of roughly 1.6 to 2.6 million — a statement a clinician can check, unlike the dollar figure. Fifth, against the population denominator: $20.00 billion over the IDF's 589 million adults with diabetes is $34 per person per year, and 1.6 to 2.6 million pump users is 0.27% to 0.44% of that population, 252 million of whom are undiagnosed. Finally, the blended rate was tested against company growth: Beta Bionics grew 54%, Insulet 31.6%, Tandem 12% and Medtronic Diabetes 10.7% in FY2025, while GMI's own syringe, strip and pen-needle segments compound at 2% to 4.5%, so the published 7.9% is the average of two unrelated businesses and describes neither. These are scope and plausibility tests, not market estimates. They do not establish the correct figure for any segment. Regional and country splits are published as empty arrays because the only source offering them presents no method, and no vendor market share is published because none is disclosed and the disclosures that exist are not comparable: Insulet's revenue is consumables, Medtronic's includes CGM, and Tandem's is being restructured by a pricing-model change that reduces reported revenue while patient volume rises.

11

Strategic Takeaways

Forecast the two halves separately. Pen needles, syringes and strips are about $5.00 billion growing 2-4.5%; pumps and pods are about $7.40 billion whose vendors grew 10.7% to 54% in FY2025. The published 7.9% describes neither.

Use patients, not dollars. Insulet, Tandem and Beta Bionics publish user counts with revenue — $4,500, about $3,383 and $2,865 per patient per year. Inverting the published total gives 1.6-2.6 million pump users, which you can sanity-check against clinical reality.

Note that the published pump segment is already full. Five disclosures account for 93.3% of it, leaving about $495 million for Roche, Sequel, Medtrum, Equil, SOOIL and all Chinese and Indian vendors combined.

Expect reported revenue to understate adoption from 2026. Tandem's guidance carries $85-95 million of pharmacy-channel headwind while shipments grow 10-11%, and Beta Bionics' pharmacy share of new starts went from high single digits to the high twenties in a year.

Remember that the biggest segment is invisible. Insulin pens are about 38% of the published market and neither Novo Nordisk nor Eli Lilly reports pen hardware separately from the insulin inside it, so that part of any estimate cannot be checked at all.

12

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.